Canaccord Genuity maintains a 'Buy' on Anacor Pharmaceuticals (ANAC); Positive on Novel Oxaborole Compounds
Tweet
Share
E-mailGet Alerts ANAC Hot Sheet
Price: $10.19 --0%
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Anacor Pharmaceuticals (NASDAQ: ANAC) price target of $11.00.
Analyst, George Farmer, said, "We remain buyers of ANAC shares on our positive view of four mid- to late-stage novel oxaborole compounds positioned to address large derm/anti-infective markets."
"In coming months ,we expect MUSE and tolerability data from small routine Phase II bridging studies evaluating PDE4 inhibitor AN2728 in psoriasis and outcomes of a deeper analysis of positive Phase II trials evaluating AN2728 and AN2898 in atopic dermatitis (AD)...Less appreciated, in our view, is potential of GSK’052, a first-in-class LeuRS inhibitor that is highly potent against a broad range of lethal Gram neg microbes."
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $7.42 yesterday.
Analyst, George Farmer, said, "We remain buyers of ANAC shares on our positive view of four mid- to late-stage novel oxaborole compounds positioned to address large derm/anti-infective markets."
"In coming months ,we expect MUSE and tolerability data from small routine Phase II bridging studies evaluating PDE4 inhibitor AN2728 in psoriasis and outcomes of a deeper analysis of positive Phase II trials evaluating AN2728 and AN2898 in atopic dermatitis (AD)...Less appreciated, in our view, is potential of GSK’052, a first-in-class LeuRS inhibitor that is highly potent against a broad range of lethal Gram neg microbes."
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $7.42 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
